This study is a single center, open label, fixed sequence drug interaction study to evaluate the effects of CYP3A4 inhibitor itraconazole and CYP3A4 inducer rifampicin on the pharmacokinetic characteristics of a single oral dose of flonotinib maleate tablets. This trial includes screening period, baseline period, medication observation period, and follow-up period, totaling approximately 3 months.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Day 1 and Day 12 : 75mg Flonoltinib on an empty stomach in the morning
Day 1 and Day 19 : 100mg Flonoltinib on an empty stomach in the morning
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Cmax
Time frame: Until 144hours
Tmax
Time frame: Until 144hours
AUC0-t
Time frame: Until 144hours
t1/2
Time frame: Until 144hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.